The outlook of companies tied to Viagra's legacy presents a complex investment scenario . While the initial surge generated substantial gains, generic competition have significantly impacted revenue. Investing in associated pharmaceutical firms now requires a careful assessment of patent safeguards, evolving healthcare changes, and the prospect for